Literature DB >> 36040592

Cardiac Gene Delivery in Large Animal Models: Antegrade Techniques.

Spyros A Mavropoulos1, Kelly P Yamada1, Tomoki Sakata1, Kiyotake Ishikawa2.   

Abstract

Percutaneous antegrade coronary injection is among the least invasive cardiac selective gene delivery methods. However, the transduction efficiency of a simple bolus antegrade injection is quite low. In order to improve transduction efficiency in antegrade intracoronary delivery, several additional approaches have been proposed.In this chapter, we will describe the important elements associated with intracoronary delivery methods and present protocols for three different catheter-based antegrade gene delivery techniques in a preclinical large animal model. This is the second edition of this chapter, and it includes modifications we have made over the past several years that further enhance transduction efficacy.
© 2022. The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Balloon occlusion; Cardiovascular diseases; Gene delivery; Gene therapy; Homogenous distribution; Impella; Intracoronary; Minimally invasive; Vectors

Mesh：

Year:  2022        PMID： 36040592     DOI： 10.1007/978-1-0716-2707-5_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN： 1064-3745


  17 in total

Review 1.  Cardiac gene therapy in large animals: bridge from bench to bedside.

Authors:  K Ishikawa; L Tilemann; D Ladage; J Aguero; L Leonardson; K Fish; Y Kawase
Journal:  Gene Ther       Date:  2012-02-02       Impact factor: 5.250

2.  Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial.

Authors:  H Kirk Hammond; William F Penny; Jay H Traverse; Timothy D Henry; Matthew W Watkins; Clyde W Yancy; Ranya N Sweis; Eric D Adler; Amit N Patel; David R Murray; Robert S Ross; Valmik Bhargava; Alan Maisel; Denise D Barnard; N Chin Lai; Nancy D Dalton; Martin L Lee; Sanjiv M Narayan; Daniel G Blanchard; Mei Hua Gao
Journal:  JAMA Cardiol       Date:  2016-05-01       Impact factor: 14.676

Review 3.  Percutaneous approaches for efficient cardiac gene delivery.

Authors:  Kiyotake Ishikawa; Jaume Aguero; Charbel Naim; Kenneth Fish; Roger J Hajjar
Journal:  J Cardiovasc Transl Res       Date:  2013-06-08       Impact factor: 4.132

4.  Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure.

Authors:  Kiyotake Ishikawa; Kenneth M Fish; Lisa Tilemann; Kleopatra Rapti; Jaume Aguero; Carlos G Santos-Gallego; Ahyoung Lee; Ioannis Karakikes; Chaoqin Xie; Fadi G Akar; Yuichi J Shimada; Judith K Gwathmey; Aravind Asokan; Scott McPhee; Jade Samulski; Richard Jude Samulski; Daniel C Sigg; Thomas Weber; Evangelia G Kranias; Roger J Hajjar
Journal:  Mol Ther       Date:  2014-07-15       Impact factor: 11.454

5.  AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling.

Authors:  Kenneth M Fish; Dennis Ladage; Yoshiaki Kawase; Ioannis Karakikes; Dongtak Jeong; Hung Ly; Kiyotake Ishikawa; Lahouaria Hadri; Lisa Tilemann; Jochen Muller-Ehmsen; R Jude Samulski; Evangelia G Kranias; Roger J Hajjar
Journal:  Circ Heart Fail       Date:  2012-12-27       Impact factor: 8.790

6.  How to optimize in vivo gene transfer to cardiac myocytes: mechanical or pharmacological procedures?

Authors:  D Logeart; S N Hatem; M Heimburger; A Le Roux; J B Michel; J J Mercadier
Journal:  Hum Gene Ther       Date:  2001-09-01       Impact factor: 5.695

7.  Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.

Authors:  Jean-Sébastien Hulot; Joe-Elie Salem; Alban Redheuil; Jean-Philippe Collet; Shaida Varnous; Patrick Jourdain; Damien Logeart; Estelle Gandjbakhch; Claude Bernard; Stéphane N Hatem; Richard Isnard; Philippe Cluzel; Claude Le Feuvre; Pascal Leprince; Nadjib Hammoudi; François M Lemoine; David Klatzmann; Eric Vicaut; Michel Komajda; Gilles Montalescot; Anne-Marie Lompré; Roger J Hajjar
Journal:  Eur J Heart Fail       Date:  2017-04-10       Impact factor: 15.534

8.  Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.

Authors:  Yoshiaki Kawase; Hung Q Ly; Fabrice Prunier; Djamel Lebeche; Yanfen Shi; Hongwei Jin; Lahouaria Hadri; Ryuichi Yoneyama; Kozo Hoshino; Yoshiaki Takewa; Susumu Sakata; Richard Peluso; Krisztina Zsebo; Judith K Gwathmey; Jean-Claude Tardif; Jean-François Tanguay; Roger J Hajjar
Journal:  J Am Coll Cardiol       Date:  2008-03-18       Impact factor: 24.094

9.  Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).

Authors:  Barry Greenberg; Alex Yaroshinsky; Krisztina M Zsebo; Javed Butler; G Michael Felker; Adriaan A Voors; Jeffrey J Rudy; Kim Wagner; Roger J Hajjar
Journal:  JACC Heart Fail       Date:  2014-01-25       Impact factor: 12.035

10.  SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure.

Authors:  Lisa Tilemann; Ahyoung Lee; Kiyotake Ishikawa; Jaume Aguero; Kleopatra Rapti; Carlos Santos-Gallego; Erik Kohlbrenner; Kenneth M Fish; Changwon Kho; Roger J Hajjar
Journal:  Sci Transl Med       Date:  2013-11-13       Impact factor: 17.956
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.